DIJON, France--ONCODESIGN (Paris:ALONC) (Alternext - ALONC) announced today that it has successfully reached a major milestone in its joint discovery collaboration with UCB that applies to ...
Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics that promote remyelination for the treatment of neurological diseases such ...
MORRIS PLAINS, New Jersey and BRUSSELS, Dec. 14, 2010 (GLOBE NEWSWIRE) -- Immunomedics Inc. (Nasdaq:IMMU) and UCB (EURONEXT:UCB) today announced the enrollment of the first patient into EMBODY™ 1, one ...
BRUSSELS, Belgium I July 28, 2015 I UCB today announced that the two EMBODY™ Phase 3 clinical studies for epratuzumab in Systemic Lupus Erythematosus (SLE) did not meet their primary clinical efficacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback